Skip to main content

Ionis exercises an option in its drug development partnership with Philadelphia's Aro Biotherapeutics

The total value of the partnership signed late last year could be worth as much as $1.4 billion for Philadelphia-based Aro.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.